Oropharynx Squamous Cell Carcinoma Clinical Trial
Official title:
SURVEILLE-HPV: National, Multicenter, Open-label, Randomized, Phase II Study Evaluating HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
SURVEILLE-HPV - A new post therapeutic surveillance strategy for HPV-driven oropharyngeal cancer based on HPV Circulating DNA measures. HPV-positive oropharyngeal cancer patients have a much better prognosis that their HPV-negative counterparts. Despite this, Post Treatment Surveillance (PTS) strategy does not take into account HPV status. HPV Circulating DNA (HPV Ct DNA) has emerged as a promising tool to assess the risk of cancer recurrence following treatment. We assume that this biomarker could be helpful to guide PTS. The number of systematic PTS visits could be significantly reduced in patients with undetectable HPV Ct DNA whereas a closer clinical and radiological follow up could be performed in case of detectable HPV Ct DNA. If confirmed, this new strategy could have several benefits including: - reduction of PTS visits for most HPV-positive patients which implies a potential cost decrease and - Identification of relapse at early stages (before the occurrence of symptoms)
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03829722 -
Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
|
Phase 2 | |
| Recruiting |
NCT04359199 -
QUantitative Assessment of Swallowing After Radiation (QUASAR)
|
||
| Suspended |
NCT04916002 -
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04564989 -
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
|
||
| Active, not recruiting |
NCT03715946 -
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
|
Phase 2 | |
| Recruiting |
NCT05451303 -
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
|
||
| Recruiting |
NCT04858269 -
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
|
Phase 2 | |
| Recruiting |
NCT05278039 -
Training Swallowing Initiation During Expiration
|
N/A | |
| Recruiting |
NCT05649865 -
Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)
|
||
| Recruiting |
NCT06088381 -
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
|
Phase 2 | |
| Recruiting |
NCT04124198 -
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
|
N/A | |
| Recruiting |
NCT02663583 -
Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell
|
||
| Withdrawn |
NCT04892875 -
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT05904327 -
Circulating Biomarkers in Oropharyngeal Cancers
|
||
| Active, not recruiting |
NCT03381183 -
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT04445064 -
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.
|
Phase 2 | |
| Recruiting |
NCT04725396 -
Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC
|
N/A | |
| Completed |
NCT03148665 -
Saliva-based Detection of CD44
|